Seino Y, Yamazaki Y
Proc Jpn Acad Ser B Phys Biol Sci. 2025; 101(2):68-74.
PMID: 39924177
PMC: 11893219.
DOI: 10.2183/pjab.101.009.
Murano T, Okada H, Hamaguchi M, Kurogi K, Tatsumi Y, Murata H
J Occup Health. 2024; 66(1).
PMID: 39572004
PMC: 11659593.
DOI: 10.1093/joccuh/uiae071.
Horie I, Abiru N
Diabetol Int. 2024; 15(3):353-361.
PMID: 39101175
PMC: 11291794.
DOI: 10.1007/s13340-024-00705-w.
Pixner T, Chaikouskaya T, Lauth W, Zimmermann G, Morwald K, Lischka J
Front Endocrinol (Lausanne). 2024; 15:1368570.
PMID: 39027470
PMC: 11254805.
DOI: 10.3389/fendo.2024.1368570.
Hamasaki A, Harada N, Muraoka A, Yamane S, Joo E, Suzuki K
Front Endocrinol (Lausanne). 2024; 15:1301352.
PMID: 38966210
PMC: 11222327.
DOI: 10.3389/fendo.2024.1301352.
Insulin:Glucagon Bipolar Axis in Obesity With a Glimpse Into Its Association With Insulin Resistance in Different Glucose Tolerance States.
Lyngdoh J, Chutia H, Sundaram S, Lakshmi V, Ruram A, Lynrah K
Cureus. 2024; 16(4):e58942.
PMID: 38665134
PMC: 11044079.
DOI: 10.7759/cureus.58942.
Lowest Glucagon/Highest C-Peptide in Oral Glucose Tolerance Test: Clinical Utility in Monitoring Glucose Control in Type 2 Diabetes Mellitus.
Chang L, Ma X, Yuan M, Ding L, Gu Y, Liu L
Diabetes Metab Syndr Obes. 2024; 17:1769-1780.
PMID: 38645659
PMC: 11032662.
DOI: 10.2147/DMSO.S459392.
Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.
Kawaguchi Y, Hajika Y, Rinka M, Masumoto K, Sawa J, Hamazaki K
J Diabetes Investig. 2024; 15(5):598-607.
PMID: 38258482
PMC: 11060164.
DOI: 10.1111/jdi.14151.
Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions - a narrative review.
Huber H, Schieren A, Holst J, Simon M
Am J Clin Nutr. 2024; 119(3):599-627.
PMID: 38218319
PMC: 10972717.
DOI: 10.1016/j.ajcnut.2024.01.007.
Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment.
Yamada H, Morimoto J, Funazaki S, Tonezawa S, Takahashi A, Yoshida M
J Clin Med Res. 2023; 15(8-9):406-414.
PMID: 37822852
PMC: 10563818.
DOI: 10.14740/jocmr4995.
Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.
Kubota M, Yamamoto K, Yoshiyama S
Cureus. 2023; 15(10):e46490.
PMID: 37800161
PMC: 10550307.
DOI: 10.7759/cureus.46490.
J-shape relationship between normal fasting plasma glucose and risk of type 2 diabetes in the general population: results from two cohort studies.
He L, Zheng W, Li Z, Chen L, Kong W, Zeng T
J Transl Med. 2023; 21(1):175.
PMID: 36872318
PMC: 9985867.
DOI: 10.1186/s12967-023-04006-9.
A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.
Seino Y, Miyoshi H, Bosch Traberg H, Divyalasya T, Nishijima K, Terauchi Y
J Diabetes Investig. 2022; 13(8):1321-1329.
PMID: 35285173
PMC: 9340870.
DOI: 10.1111/jdi.13789.
High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides.
Ueno S, Seino Y, Hidaka S, Maekawa R, Takano Y, Yamamoto M
Nutrients. 2022; 14(5).
PMID: 35267952
PMC: 8912298.
DOI: 10.3390/nu14050975.
Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin following Ingestion of Different Classes of Macronutrients.
Gobl C, Morettini M, Salvatori B, Alsalim W, Kahleova H, Ahren B
Nutrients. 2022; 14(2).
PMID: 35057557
PMC: 8780023.
DOI: 10.3390/nu14020376.
The Risk Factors for Development of Type 2 Diabetes: Panasonic Cohort Study 4.
Saijo Y, Okada H, Hamaguchi M, Habu M, Kurogi K, Murata H
Int J Environ Res Public Health. 2022; 19(1).
PMID: 35010830
PMC: 8744947.
DOI: 10.3390/ijerph19010571.
Fasting plasma glucose level in the range of 90-99 mg/dL and the risk of the onset of type 2 diabetes: Population-based Panasonic cohort study 2.
Munekawa C, Okada H, Hamaguchi M, Habu M, Kurogi K, Murata H
J Diabetes Investig. 2021; 13(3):453-459.
PMID: 34624178
PMC: 8902401.
DOI: 10.1111/jdi.13692.
The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes.
Yoo S, Kim D, Koh G
J Clin Med. 2021; 10(11).
PMID: 34199839
PMC: 8200068.
DOI: 10.3390/jcm10112487.
Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes.
Abe T, Matsubayashi Y, Muragishi S, Yoshida A, Suganami H, Furusawa K
J Diabetes Investig. 2021; 12(10):1805-1815.
PMID: 33751849
PMC: 8504901.
DOI: 10.1111/jdi.13543.
Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.
Ito A, Horie I, Miwa M, Sako A, Niri T, Nakashima Y
J Diabetes Investig. 2020; 12(8):1367-1376.
PMID: 33369175
PMC: 8354509.
DOI: 10.1111/jdi.13486.